Obesity Drug

The FDA is taking another look at an experimental obesity drug.

An advisory panel will consider the approval of lorcaserin, which blocks appetite signals to the brain.

The FDA rejected the drug in 2010 because of its potential cancer and heart risk.

However, the drug company is presenting new data, that it believes shows the drug is safe.